Health Economics›Melanoma›Advanced or metastatic disease TKI-naive

Advanced or metastatic disease TKI-naive

Melanoma · 3 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Imatinib monotherapy Variant #16	KIT	R 2 801	28d	~20.0 mo	~53.0 mo	~2	~R 5 603 PFS proxy · indirect	8
Dacarbazine monotherapy Variant #01	NRAS	R 2 608	21d	1.5 mo	9.6 mo	2	R 5 217 PFS proxy	6
Binimetinib monotherapy Variant #01 Partial	NRAS	—	21d	2.8 mo	—	2	—	1

3 of 3 regimens shown